Batea Oncology is developing a mechanomedicine platform that applies the mechanical properties of cancer cells to trap and alter residual tumor cells after surgery, beginning with glioblastoma. Its lead product, GlioHook, is a Class III implantable polycarbonate–polyurethane scaffold coated with bovine collagen designed to be stiffer than brain tissue so infiltrating tumor cells migrate into and adhere within the device. Mechanical confinement within GlioHook is claimed to reduce DNA repair and adaptive resistance pathways, increasing tumor-cell sensitivity to radiotherapy. The company has finalized GMP manufacturing, completed its regulatory preclinical package, and received Ethics Committee clearance for a first-in-human trial of 15 newly diagnosed glioblastoma patients with enrollment expected in Q4 2026. Batea plans to expand its mechanomedicine approach beyond glioblastoma to other solid tumors with high recurrence such as soft tissue sarcoma and is investigating combinations with immunotherapies. The company is based in Santiago de Compostela and has raised more than €3.1 million to date while currently closing an €8.5 million Series A to support clinical development and regulatory progression.

Total raised

$4M

Funding rounds

2

Latest round

Series A

Latest activity

Jul 2026